InflaRx N.V.(IFRX) - 2023 Q4 - Annual Report

Exhibit 99.1 InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans InflaRx will host a virtual pipeline update call today, beginning at 8:00 AM ET / 1:00 PM CET to discuss its focus on immuno- dermatology. The company will provide details on the development rationales for its chosen indications for its oral C5aR inhibitor INF904 and provide an update on the development of vilobelimab in PG. To participate in the conference call, participants may pre-register at https://us06web.zoom.u ...